ロード中...
Hyperprogressive Disease in the Irradiation Field after a Single Dose of Nivolumab for Gastric Cancer: A Case Report
Following the ATTRACTION-2 study, nivolumab was approved for advanced gastric cancer in Japan. However, pseudoprogression and hyperprogressive disease have been reported in patients treated with immune checkpoint inhibitors. We report a patient with gastric cancer who received nivolumab after radiot...
保存先:
| 出版年: | Case Rep Oncol |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
S. Karger AG
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5903152/ https://ncbi.nlm.nih.gov/pubmed/29681813 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000487477 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|